Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function.

Background: A novel, ultra-low energy nanosecond laser (retinal rejuvenation therapy) has been developed with the aim to slow progression of early age-related macular degeneration (AMD). The safety, changes in fundus characteristics and macular function in a cohort of participants with bilateral intermediate AMD are reported.

Design: Prospective non-randomised, pilot intervention study.

Fatal ischemic stroke complicating acute multifocal placoid pigment epitheliopathy: histopathological findings.

A previously healthy 29-year-old man was admitted to a tertiary referral center with acute left hemiparesis followed shortly by de novo convulsive status epilepticus. This was in the context of a 2-month history of flu-like symptoms, severe headaches, and retinopathy recently diagnosed as acute multifocal placoid pigment epitheliopathy. Neuroimaging demonstrated bilateral, multiple territory cerebral infarction.

Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.

Purpose: To investigate the potential influences that affect visual acuity (VA) outcome in a clinic-based cohort of age-related macular degeneration (AMD) patients undergoing anti-vascular endothelial growth factor (anti-VEGF) treatment for choroidal neovascularization.

Design: Prospective interventional case series.

Methods: Patients with subfoveal choroidal neovascularization (CNV) secondary to AMD were prospectively recruited.

Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD.

Purpose: Anti-vascular endothelial growth factor (anti-VEGF) drugs have dramatically improved the treatment of neovascular AMD. In pivotal studies, almost 90% of patients maintain vision, with approximately 30% showing significant improvement. Despite these successes, 10% to 15% of patients continue to lose vision, even with treatment.

Erectile dysfunction following intravitreal bevacizumab.

Despite initial concerns regarding systemic complications, the use of intravitreal antivascular endothelial growth factor (anti-VEGF) agents for ocular disease is rapidly expanding worldwide, in terms of both the number of patients injected and its indications. To our knowledge, there are no cases in the literature reporting erectile dysfunction following the use of intravitreal bevacizumab. We postulate an organic mechanism for impaired erectile function due to systemically absorbed intravitreal bevacizumab.

Prandial presbyopia.

Loss of accommodation amplitude during eating (prandial presbyopia) is a rare phenomenon that has been reported in only 1 patient who had had head trauma. We report 2 patients who had not had head trauma and whose accommodative amplitudes, measured by dynamic retinoscopy, became markedly diminished within 1 minute of starting a meal and did not recover for 55-60 minutes. Apart from this abnormality, there appeared to be no autonomic or other neurologic dysfunction.

Failure of prophylactic retinopexy in fellow eyes without a posterior vitreous detachment.

Objective: To describe adverse sequelae of retinal prophylaxis in fellow eyes of patients with rhegmatogenous retinal detachment.

Design: Records were reviewed for 17 patients who had retinal breaks or detachment subsequent to prophylactic retinopexy applied to the fellow eye (without posterior vitreous detachment) at the time of primary rhegmatogenous retinal detachment surgery. Subsequent treatment included cryotherapeutic and laser retinopexy, scleral buckling, and vitrectomy.